2024 ICD-10-CM Diagnosis Code T46.7X5S
Adverse effect of peripheral vasodilators, sequela
- ICD-10-CM Code:
- T46.7X5S
- ICD-10 Code for:
- Adverse effect of peripheral vasodilators, sequela
- Is Billable?
- Yes - Valid for Submission
- Chronic Condition Indicator: [1]
- Not chronic
- Code Navigator:
- Code Information
- Approximate Synonyms
- Clinical Classification
- Clinical Information
- Coding Guidelines
- Tabular List of Diseases and Injuries
- Code Edits
- Diagnostic Related Groups Mapping
- Present on Admission (POA)
- Convert to ICD-9 Code
- Table of Drugs and Chemicals
- Patient Education
- Other Codes Used Similar Conditions
- Code History
T46.7X5S is a billable diagnosis code used to specify a medical diagnosis of adverse effect of peripheral vasodilators, sequela. The code is valid during the current fiscal year for the submission of HIPAA-covered transactions from October 01, 2023 through September 30, 2024. The code is exempt from present on admission (POA) reporting for inpatient admissions to general acute care hospitals.
This code describes a circumstance which influences the patient's health status but not a current illness or injury. The code is unacceptable as a principal diagnosis.
T46.7X5S is a sequela code, includes a 7th character and should be used for complications that arise as a direct result of a condition like adverse effect of peripheral vasodilators. According to ICD-10-CM Guidelines a "sequela" code should be used for chronic or residual conditions that are complications of an initial acute disease, illness or injury. The most common sequela is pain. Usually, two diagnosis codes are needed when reporting sequela. The first code describes the nature of the sequela while the second code describes the sequela or late effect.
Approximate Synonyms
The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:
- Adverse reaction to bamethan
- Adverse reaction to dihydroergocornine and/or dihydroergocristine and/or dihydroergocryptine
- Adverse reaction to smooth muscle relaxant
- Adverse reaction to tolazoline
- Adverse reaction to xanthine and/or xanthine derivative
- Alprostadil adverse reaction
- Betahistine adverse reaction
- Cyclandelate adverse reaction
- E series prostaglandin adverse reaction
- Ergot alkaloid adverse reaction
- Flosequinan adverse reaction
- Inositol adverse reaction
- Inositol nicotinate adverse reaction
- Isoxsuprine adverse reaction
- Minoxidil adverse reaction
- Moxisylyte adverse reaction
- Naftidrofuryl adverse reaction
- Nicofuranose adverse reaction
- Nicotinic acid adverse reaction
- Nicotinyl alcohol adverse reaction
- Pentoxifylline adverse reaction
- Phenoxybenzamine adverse reaction
- Phentolamine adverse reaction
Clinical Classification
Clinical Category is Poisoning/toxic effect/adverse effects/underdosing, sequela
- CCSR Category Code: INJ075
- Inpatient Default CCSR: X - Not applicable.
- Outpatient Default CCSR: Y - Yes, default outpatient assignment for principal diagnosis or first-listed diagnosis.
Clinical Information
Alprostadil
a potent vasodilator agent that increases peripheral blood flow.Bencyclane
a vasodilator agent found to be effective in a variety of peripheral circulation disorders. it has various other potentially useful pharmacological effects. its mechanism may involve block of calcium channels.Betahistine
a histamine analog and h1 receptor agonist that serves as a vasodilator. it is used in meniere disease and in vascular headaches but may exacerbate bronchial asthma and peptic ulcers.Cyclandelate
a direct-acting smooth muscle relaxant used to dilate blood vessels.Dihydroergocornine
a 9,10alpha-dihydro derivative of ergotamine that contains isopropyl sidechains at the 2' and 5' positions of the molecule.Dihydroergotoxine
a mixture of three different hydrogenated derivatives of ergotamine: dihydroergocornine; dihydroergocristine; and dihydroergocryptine. dihydroergotoxine has been proposed to be a neuroprotective agent and a nootropic agent. the mechanism of its therapeutic actions is not clear, but it can act as an alpha-adrenergic antagonist and a dopamine agonist. the methanesulfonate salts of this mixture of alkaloids are called ergoloid mesylates.Ergoloid Mesylates
a mixture of the mesylates (methane sulfonates) of dihydroergocornine; dihydroergocristine; and the alpha- and beta-isomers of dihydroergocryptine. the substance produces a generalized peripheral vasodilation and a fall in arterial pressure and has been used to treat symptoms of mild to moderate impairment of mental function in the elderly.Flunarizine
flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine h1 blocking activity. it is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.Iloprost
an eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism. it is a stable and synthetic analog of epoprostenol, but with a longer half-life than the parent compound. its actions are similar to prostacyclin. iloprost produces vasodilation and inhibits platelet aggregation.Isoxsuprine
a beta-adrenergic agonist that causes direct relaxation of uterine and vascular smooth muscle. its vasodilating actions are greater on the arteries supplying skeletal muscle than on those supplying skin. it is used in the treatment of peripheral vascular disease and in premature labor.Minoxidil
a potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure. (from martindale, the extra pharmacopoeia, 30th ed, p371)Moxisylyte
an alpha-adrenergic blocking agent that is used in raynaud's disease. it is also used locally in the eye to reverse the mydriasis caused by phenylephrine and other sympathomimetic agents. (from martindale, the extra pharmacopoeia, 30th ed, p1312)Niacin
a water-soluble vitamin of the b complex occurring in various animal and plant tissues. it is required by the body for the formation of coenzymes nad and nadp. it has pellagra-curative, vasodilating, and antilipemic properties.Niacinamide
an important compound functioning as a component of the coenzyme nad. its primary significance is in the prevention and/or cure of blacktongue and pellagra. most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake.Xanthinol Niacinate
a vasodilator used in peripheral vascular disorders and insufficiency. it may cause gastric discomfort and hypotension.Nicergoline
an ergot derivative that has been used as a cerebral vasodilator and in peripheral vascular disease. it may ameliorate cognitive deficits in cerebrovascular disorders.Nicotinyl Alcohol
alcohol analog of nicotinic acid which is a direct-acting peripheral vasodilator that causes flushing and may decrease blood pressure. it is used in vasospasm and threatened gangrene.Nylidrin
a beta-adrenergic agonist. nylidrin causes peripheral vasodilation, a positive inotropic effect, and increased gastric volume of gastric juice. it is used in the treatment of peripheral vascular disorders and premature labor.Pentoxifylline
a methylxanthine derivative that inhibits phosphodiesterase and affects blood rheology. it improves blood flow by increasing erythrocyte and leukocyte flexibility. it also inhibits platelet aggregation. pentoxifylline modulates immunologic activity by stimulating cytokine production.Phenoxybenzamine
an alpha-adrenergic antagonist with long duration of action. it has been used to treat hypertension and as a peripheral vasodilator.Phentolamine
a nonselective alpha-adrenergic antagonist. it is used in the treatment of hypertension and hypertensive emergencies, pheochromocytoma, vasospasm of raynaud disease and frostbite, clonidine withdrawal syndrome, impotence, and peripheral vascular disease.Suloctidil
a peripheral vasodilator that was formerly used in the management of peripheral and cerebral vascular disorders. it is hepatotoxic and fatalities have occurred. (from martindale, the extra pharmacopoeia, 30th ed, p1312)Tadalafil
a carboline derivative and phosphodiesterase 5 inhibitor that is used primarily to treat erectile dysfunction; benign prostatic hyperplasia and primary pulmonary hypertension.Tolazoline
a vasodilator that apparently has direct actions on blood vessels and also increases cardiac output. tolazoline can interact to some degree with histamine, adrenergic, and cholinergic receptors, but the mechanisms of its therapeutic effects are not clear. it is used in treatment of persistent pulmonary hypertension of the newborn.Trimetazidine
a vasodilator used in angina of effort or ischemic heart disease.
Coding Guidelines
When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.
The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of agents primarily affecting the cardiovascular system (T46). Use the following options for the aplicable episode of care:
- A - initial encounter
- D - subsequent encounter
- S - sequela
Code Edits
The Medicare Code Editor (MCE) detects and reports errors in the coding of claims data. The following ICD-10-CM Code Edits are applicable to this code:
- Unacceptable principal diagnosis - There are selected codes that describe a circumstance which influences an individual's health status but not a current illness or injury, or codes that are not specific manifestations but may be due to an underlying cause. These codes are considered unacceptable as a principal diagnosis.
Present on Admission (POA)
T46.7X5S is exempt from POA reporting - The Present on Admission (POA) indicator is used for diagnosis codes included in claims involving inpatient admissions to general acute care hospitals. POA indicators must be reported to CMS on each claim to facilitate the grouping of diagnoses codes into the proper Diagnostic Related Groups (DRG). CMS publishes a listing of specific diagnosis codes that are exempt from the POA reporting requirement. Review other POA exempt codes here.
CMS POA Indicator Options and Definitions
POA Indicator | Reason for Code | CMS will pay the CC/MCC DRG? |
---|---|---|
Y | Diagnosis was present at time of inpatient admission. | YES |
N | Diagnosis was not present at time of inpatient admission. | NO |
U | Documentation insufficient to determine if the condition was present at the time of inpatient admission. | NO |
W | Clinically undetermined - unable to clinically determine whether the condition was present at the time of inpatient admission. | YES |
1 | Unreported/Not used - Exempt from POA reporting. | NO |
Convert T46.7X5S to ICD-9-CM
- ICD-9-CM Code: 909.5 - Lte efct advrs efct drug
Combination Flag - Multiple codes are needed to describe the source diagnosis code. Correct coding should be done based on contextual judgment. - ICD-9-CM Code: E942.5 - Adv eff vasodilators NEC
Combination Flag - Multiple codes are needed to describe the source diagnosis code. Correct coding should be done based on contextual judgment.
Table of Drugs and Chemicals
The parent code T46.7X5 of the current diagnosis code is referenced in the Table of Drugs and Chemicals, this table contains a classification of drugs, industrial solvents, corrosive gases, noxious plants, pesticides, and other toxic agents.
According to ICD-10-CM coding guidelines it is advised to do not code directly from the Table of Drugs and Chemicals, instead always refer back to the Tabular List when doing the initial coding. Each substance in the table is assigned a code according to the poisoning classification and external causes of adverse effects. It is important to use as many codes as necessary to specify all reported drugs, medicinal or chemical substances. If the same diagnosis code describes the causative agent for more than one adverse reaction, poisoning, toxic effect or underdosing, utilize the code only once.
Patient Education
Drug Reactions
Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.
What is a drug interaction?
A drug interaction is a change in the way a drug acts in the body when taken with certain other drugs, foods, or supplements or when taken while you have certain medical conditions. Examples include:
- Two drugs, such as aspirin and blood thinners
- Drugs and food, such as statins and grapefruit
- Drugs and supplements, such as gingko and blood thinners
- Drugs and medical conditions, such as aspirin and peptic ulcers
Interactions could cause a drug to be more or less effective, cause side effects, or change the way one or both drugs work.
What are side effects?
Side effects are unwanted, usually unpleasant, effects caused by medicines. Most are mild, such as a stomachache, dry mouth, or drowsiness, and go away after you stop taking the medicine. Others can be more serious. Sometimes a drug can interact with a disease that you have and cause a side effect. For example, if you have a heart condition, certain decongestants can cause you to have a rapid heartbeat.
What are drug allergies?
Drug allergies are another type of reaction. They can range from mild to life-threatening. Skin reactions, such as hives and rashes, are the most common type. Anaphylaxis, a serious allergic reaction, is less common.
How can I stay safe when taking medicines?
When you start a new prescription or over-the-counter medicine, make sure you understand how to take it correctly. Know which other medicines, foods, and supplements you need to avoid. Always talk to your health care provider or pharmacist if you have questions about your medicines.
[Learn More in MedlinePlus]
Code History
- FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
- FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
- FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
- FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
- FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
- FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
- FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
- FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
- FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.
Footnotes
[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.